Pfizer inks antisense drug deal worth up to $1.5B

Pfizer will front $250 million to gain rights to a phase 2 drug being developed to target a range of major diseases.

Source: PharmaManufacturing.com - October 7, 2019 Category: Pharmaceuticals Source Type: news